Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV by R. Borse, B. Randive, S. Mattoo, P. Malik, H. Solanki, A. Gupta, R.E. Chaisson, V. Mave, N. Suryavanshi

Get full text

Symplectic Approach of Three-Dimensional Palatini Theory Plus a Chern-Simons Term by Alberto Escalante, Prihel Cavildo-Sánchez

“…Using the symplectic framework of Faddeev-Jackiw, the three-dimensional Palatini theory plus a Chern-Simons term [P-CS] is analyzed. …”
Get full text

Peters Plus syndrome: a recognizable clinical entity by Gizem Ürel Demir, Naz Güleray Lafcı, Özlem Akgün Doğan, Pelin Özlem Şimşek-Kiper, Gülen Eda Utine

Subjects: “…B3GLCT…”
Get full text

Life after Methyl Bromide: Research on 1,3-Dichloropropene plus Chloropicrin in Florida by Bielinski M. Santos

Get full text

Classification of Stages 1,2,3 and Preplus, Plus disease of ROP using MultiCNN_LSTM classifier by Ranjana Agrawal, Sucheta Kulkarni, Madan Deshpande, Anita Gaikwad, Rahee Walambe, Ketan V. Kotecha

“…The fundus images were classified as without stage (Normal)/with Stage (ROP) by segmenting the ridge. Stages 1–3 were classified using machine Learning (ML) models. • This study aims to improve accuracy of Stages 1–3 classification and identify Pre-plus/ Plus disease using MultiCNN_LSTM networks. …”
Get full text

Eigen Problem Over Max-Plus Algebra on Determination of the T3 Brand Shuttlecock Production Schedule by Andra Permana, Siswanto Siswanto, Pangadi Pangadi

“…The purpose of this research is to determine the Shuttlecock T3 production schedule using eigenvalue and eigenvector in max-plus algebra. …”
Get full text

ANALYSIS OF THREE SERVERS CLOSED SERIES QUEUING NETWORK WITH DELAY TIME USING MAX-PLUS ALGEBRA by Marcellinus Andy Rudhito, Dewa Putu Wiadnyana Putra

“…The results show that the max-plus eigenvalue of a closed series queuing network with 3 servers, which is also the periodicity of network dynamics, is the largest service time of the server in the network. …”
Get full text

Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2− advanced breast cancer: Final results of the randomized phase III MONARCH plus trial by Xichun Hu, Qingyuan Zhang, Tao Sun, Yongmei Yin, Huiping Li, Min Yan, Zhongsheng Tong, Man Li, Yue’e Teng, Christina Pimentel Oppermann, Govind Babu Kanakasetty, MA Coccia Portugal, Liu Yang, Wanli Zhang, Zefei Jiang, Sihan Zhou, Xiuyuan Hao

“…Methods:. In the phase III MONARCH plus study, postmenopausal women in China, India, Brazil, and South Africa with HR+/HER2− ABC without prior systemic therapy in an advanced setting (cohort A) or progression on prior ET (cohort B) were randomized (2:1) to abemaciclib (150 mg twice daily [BID]) or placebo plus: anastrozole (1.0 mg/day) or letrozole (2.5 mg/day) (cohort A) or fulvestrant (500 mg on days 1 and 15 of cycle 1 and then on day 1 of each subsequent cycle) (cohort B). …”
Get full text

Plus and Minus by George Englebretsen

Get full text

Rémi Dalisson, Au plus près du peuple. Les voyages politiques de Napoléon III by Guillaume Cornu et Nicolas Tardits

Get full text

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin by Frank G. Rücker, Lars Bullinger, Sibylle Cocciardi, Sabrina Skambraks, Tamara J. Luck, Daniela Weber, Julia Krzykalla, Ema Pozek, Isabelle Schneider, Andrea Corbacioglu, Verena I. Gaidzik, Annika Meid, Sophia Aicher, Frank Stegelmann, Anika Schrade, Frauke Theis, Walter Fiedler, Helmut R. Salih, Gerald Wulf, Hans Salwender, Thomas Schroeder, Katharina S. Götze, Michael W. M. Kühn, Michael Lübbert, Richard F. Schlenk, Axel Benner, Felicitas Thol, Michael Heuser, Arnold Ganser, Hartmut Döhner, Konstanze Döhner

Get full text

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis by Xuan Wang, Jie Dai, Li Zhou, Hui Feng, Jun Guo, Xue Bai, Lu Si, Bixia Tang, Chuanliang Cui, Xinan Sheng, Siming Li, Zhihong Chi, Lili Mao, Bin Lian, Xieqiao Yan, Yan Kong, Xiaowen Wu, Xiongwen Tang, Keith T Flaherty

“…In contrast, a 12-GEP signature correlated with improved PFS (17.7 vs 5.7 months, p=0.0083) and OS (35.6 vs 17.6 months, p=0.039).Conclusions The 3-year survival update confirmed the antitumor activity and long-term survival benefit of the toripalimab plus axitinib combination in patients with advanced MM. …”
Get full text

Discordance of 3rd and 4th generation QuantiFERON-TB Gold assays by pregnancy stages in India by Vandana Kulkarni, Mallika Alexander, Ramesh Bhosale, Divyashri Jain, Prasad Deshpande, Emily Shira Gitlin, Arthi Vaidyanathan, Andrea Chalem, Shilpa Naik, Nikhil Gupte, Neelu Nawani, Amita Gupta, Jyoti Mathad

Get full text

PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-analysis by Chao Song, Yuan Qiu, Huan Fan, Yongqing Han

Get full text

Comment on ‘Posterior to the ridge laser in zone 2 stage 3 retinopathy of prematurity with plus disease: Efficacy and safety’ by Neha K Sethi

Get full text

Feasibility and predictive factors on the completion of docetaxel plus S‐1 adjuvant chemotherapy in pathological stage III gastric cancer by Masayoshi Terayama, Manabu Ohashi, Kensei Yamaguchi, Daisuke Takahari, Rie Makuuchi, Masaru Hayami, Satoshi Ida, Koshi Kumagai, Takeshi Sano, Souya Nunobe

“…Abstract Background The standard adjuvant chemotherapy regimen for stage III gastric cancer is docetaxel plus S‐1 (DS) based on the results of the START‐II trials. …”
Get full text

Dependency of the pulse dynamic electrochemical machining characteristics of Allvac 718 plus in NaNO3 solution on the machining paraments by Moqi Shen, Shuanglu Duan, Zhengrui Zhou, Zhichun Zhang, Jia Liu, Di Zhu

Get full text

Fractional order plus-negative sequence decoupling control strategy for dynamic voltage restorer by WU Chaojun, WANG Zhenyue, YANG Ningning, SHAO Wenquan

Subjects: Get full text

Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial by Hui Zhou, Jun Zhu, Yu Yang, Wei Yang, Liling Zhang, Lihong Liu, Mingzhi Zhang, Chuan He, Mei Zhang, Sujun Gao, Zhiming Li, Min Zhou, Hongmei Jing, Qingyuan Zhang, Ying Cheng, Yuqin Song, Zhengzi Qian, Xiuhua Sun, Wenyu Li, Haiyan Yang, Feng Yan, Ying Xiang, Bing Xu, Weihua Zhang, Xiaohong Zhang, Jie Jin, Huilan Liu, Weili Zhao, Ru Feng, Wenqi Jiang, Hong Cen, Fangfang Lv, Yunhong Huang, Ding Yu, Qunyi Guo, Lie Lin, Jianzhen Shen, Donghua Zhang, Jishi Wang, Xiongpeng Zhu, Meizuo Zhong, Jingbo Wang, Zhao Wang, Hongguo Zhao

“…Background In patients with untreated CD20-positive diffuse large B-cell lymphoma (DLBCL), a phase 3 trial was carried out to evaluate the efficacy and safety of zuberitamab plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; Hi-CHOP) versus rituximab plus CHOP (R-CHOP) treatment regimens.Methods In a 2:1 ratio, eligible patients were assigned randomly to receive treatment of six cycles of either 375 mg/m2 zuberitamab or rituximab together with conventional CHOP chemotherapy. …”
Get full text

LOW DOSE CYTARABINE PLUS SORAFENIB IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA by Tural Mahmudov

Get full text